Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
N/A
1(33.3%)
3Total
Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06263270Phase 1Completed

Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee

Role: lead

NCT02210468Phase 1Unknown

APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee

Role: lead

NCT02209662Not ApplicableUnknown

Safety and Efficacy Study of APIC-PRP in Non-healing Diabetic Foot Ulcers

Role: lead

NCT01079026Completed

Outcome After Lumbar Epidural Steroid Injection

Role: collaborator

All 4 trials loaded